EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®)

Petersen I et al. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®). Pathol Res Pract 2017; Sept 213(12). doi: 10.1016/j.prp.2017.09.021

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018; Feb;72(3):449-459. doi: 10.1111/his.13375

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Scheel AH et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; Oct;29(10):1165-72. doi: 10.1038/modpathol.2016.117

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen E et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019; Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023